SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

NCT04930315 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Apatinib Mesylate
DRUG: Camrelizumab

Sponsor

Zhejiang University